leisure time -WSS

leisure time

author：fashion 2025-10-04 03:59:24 - browse：57

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Shifting the focus from loneliness to social health

WSS

ASCO: AstraZeneca says CAR

How to increase colonoscopy rates? Looks like an AI can help

Kaiser's Risant Health gobbled up Geisinger. Who is next?

NIH documents show early flaws of $1.6 billion long Covid program

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Woman returns to dialysis after doctors remove transplanted pig kidney

leisure time

leisure time

knowledge

State Dept. review finds Biden bears some blame for Afghanistan failures

Let's speed up science by embracing open access publishing

In age of alternative facts, a scholarly course on calling out crap

Kaiser's Risant Health gobbled up Geisinger. Who is next?

After affirmative action ruling, medical educators look to 'holistic review'

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

BMI, flaws aside, is found to be useful estimate of body fat in youth

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

HIV drugs protect against transmission, even in unprotected sex

leisure time

NIH documents show early flaws of $1.6 billion long Covid program

Kaiser's Risant Health gobbled up Geisinger. Who is next?

BMI, flaws aside, is found to be useful estimate of body fat in youth

Innovation in antibiotics is ailing. 'Brain drain' may kill it

How to increase colonoscopy rates? Looks like an AI can help

NIH documents show early flaws of $1.6 billion long Covid program

knowledge

focus

hotspot

Wikipedia